Drug Profile

Bizalimogene ralaplasmid - Inovio Pharmaceuticals

Alternative Names: Human papillomavirus vaccine-VGX Pharmaceuticals; INO-3100; pGX 3001; pGX-3002; VGX-3100

Latest Information Update: 08 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Pennsylvania
Developer AIDS Malignancy Consortium; ApolloBio; Inovio Pharmaceuticals
Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies; Papillomavirus vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

31 Dec 2023 Discontinued - Phase-II for Vulvar intraepithelial neoplasia (Combination therapy) in Puerto Rico and USA (IM)
31 Dec 2023 Discontinued - Phase-II for Vulvar intraepithelial neoplasia in USA and Puerto Rico (IM)
31 Dec 2023 ApolloBio Corporation intends to file a regulatory application for Cervical intraepithelial neoplasia in China

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com